ArticleOpen forum infectious diseases2025
Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara-Bavarian Nordic Vaccination.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Distinct Inflammatory Immune Signature in Acute Mpox Associated With Proctitis.Open forum infectious diseases · 2026Article
- Article
- Durability of the Humoral Response to MPXV Infection.Journal of the International AIDS Society · 2026Review
- Immune Response to MVA-BN Vaccination for Mpox: Current Evidence and Future Directions.Vaccines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Clade IIb mpox cases have declined globally, likely due to behavioral changes alongside vaccine- and infection-induced immunity. However, infections in vaccinated individuals raise concerns about immunity durability. We compared the longevity of antibody responses following mpox infection and modified vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccination. Methods: In a multicenter, prospective cohort, we measured plasma IgG titers to vaccinia virus (VACV) B5 antigen in adults with prior mpox, MVA-BN vaccination, and historical controls, sampled up to 2 years postexposure. Receiver operating characteristic analysis determined the seropositivity threshold. Generalized additive mixed models compared antibody kinetics, and logistic regression identified factors associated with seropositivity. The results are median (interquartile range) unless specified. Results: A total of 122 vaccinated participants (100% male, aged 36 [32.5-43.5], 25% people with HIV [PWH]) were sampled at 22.0 (20.0-23.5) months post-MVA-BN vaccination, 72 of whom had a paired sample 12.5 (8.0-15.5) months prior, alongside 13 participants post-mpox (100% male, aged 32.5 [30.5-40], 23% PWH) sampled 25.0 (22.5-29.0) months postinfection, 12 with a paired sample 12.5 (8.5-15.5) months prior. At follow-up, 85% (11/13) of the post-mpox group remained seropositive, versus 32% (39/122) of the vaccinated group. Predicted geometric-mean anti-VACV-B5 titers fell below the seropositivity threshold at 15.5 (95% confidence interval [CI]: 13.0-19.5) months postvaccine. PWH had significantly lower odds of retaining seropositivity (odds ratio: 0.18; 95% CI: .04-.60; Conclusions: Antibody titers declined more rapidly postvaccination than post-mpox, with most vaccinated recipients, particularly PWH, losing seropositivity at 2 years. How these data relate to reinfection risk or the need for boosters remains to be determined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.